ATTRACTION-2 — Nivolumab Versus Placebo in Heavily Pretreated Advanced Gastric Cancer (Asian)

Phase 3 · 2017 · Gastric Cancer

Design

Randomized 2:1 to nivolumab vs placebo in patients who had progressed on 2 or more prior regimens.

Population

Heavily pretreated advanced gastric or gastroesophageal junction cancer in East Asian patients.

Primary Endpoint

overall survival (OS)

Key Result

Nivolumab improved median OS (5.3 vs 4.1 mo; HR 0.63) with durable responses and a 12-month OS of 26% vs 11%.

Guideline Impact

Basis for nivolumab approval in later-line gastric cancer in Asia